ISMMS, Boehringer Ingelheim to test nintedanib for treating pulmonary fibrosis post-COVID-19… EP News Bureau Nov 20, 2020 The primary endpoint of the study is percent change in forced vital capacity, a measurement of lung function, compared to baseline…